BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12841298)

  • 1. Pulmonary hypertension in systemic sclerosis.
    Denton CP; Black CM
    Rheum Dis Clin North Am; 2003 May; 29(2):335-49, vii. PubMed ID: 12841298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: From Bedside to Bench and Back Again.
    Bahi M; Li C; Wang G; Korman BD
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic scleroderma: Review and updated approach and case description to addressing pulmonary arterial hypertension and idiopathic pulmonary fibrosis: A dual challenge in treatment.
    Cueto-Robledo G; Tovar-Benitez D; Alfaro-Cruz A; Gonzalez-Hermosillo LM
    Curr Probl Cardiol; 2024 Apr; 49(4):102404. PubMed ID: 38232920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in pathogenesis and treatment of systemic sclerosis.
    Denton CP
    Clin Med (Lond); 2016 Feb; 16(1):55-60. PubMed ID: 26833515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Pulmonary Hypertension Caused by Pulmonary Fibrosis: A Promising Natural Killer T Cell-based Therapy.
    Wang ZH; Zhou Q
    Am J Respir Crit Care Med; 2023 Mar; 207(6):795-796. PubMed ID: 36638561
    [No Abstract]   [Full Text] [Related]  

  • 6. Does reduced cathepsin activity contribute to skin and lung fibrosis in patients with systemic sclerosis and related disorders?
    Garton M; Kelly C
    Rheumatology (Oxford); 2024 Mar; 63(3):e81-e82. PubMed ID: 37831911
    [No Abstract]   [Full Text] [Related]  

  • 7. Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.
    Ramirez A; Varga J
    Treat Respir Med; 2004; 3(6):339-52. PubMed ID: 15658881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CC Chemokines in Idiopathic Pulmonary Fibrosis: Pathogenic Role and Therapeutic Potential.
    Liu S; Liu C; Wang Q; Liu S; Min J
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
    Jimenez SA; Piera-Velazquez S
    Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of long-term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis.
    Murdaca G; Lantieri F; Puppo F; Bezante GP; Balbi M
    J Int Med Res; 2016 Sep; 44(1 suppl):85-89. PubMed ID: 27683147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and opportunities in treating inflammation associated with pulmonary hypertension.
    Voelkel NF; Tamosiuniene R; Nicolls MR
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):939-51. PubMed ID: 27096622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension.
    Qian J; Tian W; Jiang X; Tamosiuniene R; Sung YK; Shuffle EM; Tu AB; Valenzuela A; Jiang S; Zamanian RT; Fiorentino DF; Voelkel NF; Peters-Golden M; Stenmark KR; Chung L; Rabinovitch M; Nicolls MR
    Hypertension; 2015 Dec; 66(6):1227-1239. PubMed ID: 26558820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis.
    Jimenez SA
    ISRN Rheumatol; 2013 Sep; 2013():835948. PubMed ID: 24175099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelets in pulmonary hypertension: a causative role or a simple association?
    Zanjani KS
    Iran J Pediatr; 2012 Jun; 22(2):145-57. PubMed ID: 23056879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging modalities for the diagnosis of pulmonary hypertension in systemic sclerosis.
    Dimitroulas T; Mavrogeni S; Kitas GD
    Nat Rev Rheumatol; 2012 Feb; 8(4):203-13. PubMed ID: 22310183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cyclic citrullinated peptide antibodies in scleroderma patients.
    Polimeni M; Feniman D; Skare TS; Nisihara RM
    Clin Rheumatol; 2012 May; 31(5):877-80. PubMed ID: 22215120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure.
    Coral-Alvarado PX; Garces MF; Caminos JE; Iglesias-Gamarra A; Restrepo JF; Quintana G
    Int J Rheumatol; 2010; 2010():. PubMed ID: 20871866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis.
    Coral-Alvarado P; Quintana G; Garces MF; Cepeda LA; Caminos JE; Rondon F; Iglesias-Gamarra A; Restrepo JF
    Rheumatol Int; 2009 Jul; 29(9):1017-24. PubMed ID: 19116719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.
    Denton CP; Pope JE; Peter HH; Gabrielli A; Boonstra A; van den Hoogen FH; Riemekasten G; De Vita S; Morganti A; Dölberg M; Berkani O; Guillevin L;
    Ann Rheum Dis; 2008 Sep; 67(9):1222-8. PubMed ID: 18055477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.